Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTM Boost is a decellularized Human Cellular and Tissue Based Allograft (HCT/P) derived from placental connective tissue. Marketed by CTM Biomedical, it is classified by the FDA as a minimally-manipulated biologic intended for the repair of connective tissue. The product functions as a scaffold that promotes tenocyte proliferation and reduces inflammation in vitro, which is hypothesized to accelerate and enhance the healing of tendons. It is administered via injection and is currently being evaluated in a Phase 4 clinical trial by the Allegheny Singer Research Institute (Allegheny Health Network Research Institute) to determine its non-inferiority to platelet-rich plasma (PRP) in treating patients with rotator cuff tendinopathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CTM Boost.